Literature DB >> 19901721

Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis.

Shingo Konno1, Takamasa Ichijo, Mayumi Murata, Takahiro Toda, Hiroshi Nakazora, Nobuatsu Nomoto, Hideki Sugimoto, Hiroshi Nemoto, Teruyuki Kurihara, Nobuo Wakata, Toshiki Fujioka.   

Abstract

We describe a rare case of autoimmune polyglandular syndrome type 2 initially presenting as Addison disease and autoimmune thyroid disease, with subsequent development of autoimmune hepatitis and myasthenia gravis (MG) crisis in a Japanese woman. MG improved with oral prednisolone followed by plasmapheresis for immunoadsorption; thymectomy was not performed. Conventional treatment for MG was effective and safe in this case, in which there was positivity for human leukocyte antigen A23, B52, B62, DR11, and DR15.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901721     DOI: 10.1097/NRL.0b013e3181945437

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  3 in total

1.  Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course.

Authors:  Justyna Kubiszewska; Beata Szyluk; Piotr Szczudlik; Zbigniew Bartoszewicz; Małgorzata Dutkiewicz; Maksymilian Bielecki; Tomasz Bednarczuk; Anna Kostera-Pruszczyk
Journal:  Brain Behav       Date:  2016-08-04       Impact factor: 2.708

2.  Autoimmune polyglandular syndrome type 2 and autoimmune hepatitis with thymoma-associated myasthenia gravis: case report.

Authors:  Hidefumi Inaba; Hiroyuki Ariyasu; Hiroshi Iwakura; Chiaki Kurimoto; Yoko Ueda; Shinsuke Uraki; Ken Takeshima; Yasushi Furukawa; Shuhei Morita; Yoshiaki Nakayama; Takuya Ohashi; Hidefumi Ito; Yoshiharu Nishimura; Takashi Akamizu
Journal:  BMC Endocr Disord       Date:  2020-04-07       Impact factor: 2.763

3.  A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3.

Authors:  Hiroyasu Inoue; Kentaro Yamada; Asami Fujii; Tatsuya Tomonari; Kotaro Mizuno; Keiko Mita; Osamu Higuchi; Masaya Akao; Noriyuki Matsukawa
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.